Form 4: ANI Pharma Exec's Stock Award & Tax Withholding

ANI Pharmaceuticals SVP Thomas Rowland received a restricted stock award and had shares withheld for tax purposes.

Summary

• Thomas Andrew Rowland, SVP, Head Established Brands at ANI Pharmaceuticals Inc. (ANIP), reported transactions involving the company's common stock.
• On February 26, 2026, Rowland acquired 6,021 shares of common stock at a price of $77.15 per share, totaling approximately $464,500.
• This acquisition represents a restricted stock award that will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
• On February 28, 2026, Rowland disposed of 628 shares of common stock at a price of $73.9 per share, totaling approximately $46,400.
• These disposed shares were withheld for tax purposes, exempt under Rule 16(b)-3, in connection with the vesting of 2,171 shares of previously reported restricted stock.
• Following these transactions, Rowland beneficially owns 43,502 shares of ANI Pharmaceuticals Inc. common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. The grant of a restricted stock award to a senior executive indicates continued confidence in the individual and aligns their incentives with long-term company performance, despite the routine tax-related share disposition.

Positives

• SVP Thomas Rowland received a restricted stock award of 6,021 shares, aligning his interests with long-term shareholder value.
• The restricted stock award vests over four years, indicating a commitment to retaining key management personnel.

Negatives

• 628 shares were disposed of to cover tax obligations related to the vesting of previously granted restricted stock, which is a routine but dilutive event for the individual.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as restricted stock awards and subsequent tax-related dispositions, are common practices in executive compensation across the pharmaceutical industry. These awards are designed to align management's long-term interests with those of shareholders by tying a portion of their compensation to the company's stock performance.

Stakeholder Impact

• Shareholders: The restricted stock award aligns the interests of a key executive with long-term shareholder value, potentially fostering better decision-making for sustained growth.
• Employees (specifically the reporting person): The award represents a significant component of executive compensation, providing a long-term incentive and retention mechanism.

Next Steps

• The restricted stock award of 6,021 shares will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Form 4, Insider Transaction, Restricted Stock Award, Equity Compensation, Stock Ownership, Executive Compensation